Meglumine
Meglumine Information

About Meglumine

Meglumine Antimoniate is used for many diagnostic test in different concentrations such as 85% injection is used for adult angiocardiography and thoracic aortography and a 76% solution is used in excretion urography, paediatric angiocardiography and Meglumine Diatrizoate, Sodium and Sodium Meglumine is used for angiocardiography and thoracic aortography in different concentrations. Meglumine Iodoxamate is the methylglucamine salt of an ionic, water-soluble, dimeric, radiographic contrast medium; formerly used primarily for intravenous cholangiography.

Indications

Meglumine is primarily indicated in conditions like Angiography, Arthrography, Cholangiography, Cholecystography, CT enhancement, Cutaneous leishmaniasis, Duodenal ulcer associated with h. Pylori, Excretion urography, Radiological contrast agent, Splenoportography, Venography.

Contraindication

Meglumine is contraindicated in conditions like Acidosis,Asthma,Phaeochromocytoma,Thyrotoxicosis,Sickle cell anaemia,Cardiac insufficiency,Congestive heart failure,Myeloma,Pulmonary edema,Impaired renal function,Intracranial hemorrhage,Atopy,Sickle cell disease,Hypothyroidism,Dehydration,Inadequate urine flow,Hypersensitivity to the drug.

Side Effects

The severe or irreversible adverse effects of Meglumine, which give rise to further complications include Pancreatitis, Impaired renal function, Hyperthyroidism.Meglumine produces potentially life-threatening effects which include Anaphylactoid reactions, Ventricular fibrillation, Pulmonary edema, Cardiac arrhythmias, Angioneurotic edema. which are responsible for the discontinuation of Meglumine therapy.The signs and symptoms that are produced after the acute overdosage of Meglumine include Bradycardia, Hypotension, Anaphylactoid reactions, Pyrexia, Renal failure, Tremor.The symptomatic adverse reactions produced by Meglumine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Diarrhea, Fever, Abdominal pain, Chills, Rashes, Urticaria, Colitis, Itching, Hypotension, Flushing, Muscle weakness, Nausea and vomiting, Sneezing, Altered taste sensations, Faintness, Hypertension, Nodular goitre, Enteritis.

Warnings

Because of the high osmotic pressure and minimal tendency of meglumine diatrizoate to absorb from the intestine, it should not be administered to babies and young children in higher doses than those recommended, because of the additives must not be used intravenously. Liver disease may alter the response to drugs in several ways. Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present. Consider dose reduction in renal failure to avoid possibility of toxicity, increased sensitivity, and side effects.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.